Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 15, 2008, Pages 5868-5873

  McBride, Jodi L ^a   Boudreau, Ryan L ^a   Harper, Scott Q ^a,d   Staber, Patrick D ^a   Monteys, Alex Mas ^a   Martins, Inês ^a   Gilmore, Brian L ^a   Burstein, Haim ^b   Peluso, Richard W ^b   Polisky, Barry ^c   Carter, Barrie J ^b   Davidson, Beverly L ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Targeted Genetics Corporation   (United States)

^c Sirna Therapeutics Inc   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

AAV; Gene therapy; Huntington's disease; RNAi

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY RNA; MICRORNA; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TOXICITY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; DRUG SCREENING; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE INDUCTION; GENE SILENCING; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE;

ANIMALS; BRAIN; CORPUS STRIATUM; GENE SILENCING; GENE THERAPY; HUMANS; HUNTINGTON DISEASE; MICE; MICRORNAS; NEUROTOXICITY SYNDROMES; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 44449121785     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0801775105     Document Type: Article

References (21)

1. Fire A, et al. (1998) Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature 391:806-811.
2. Reinhart BJ, et al. (2000) The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403:901-906.
3. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001) Identification of novel genes coding for small expressed RNAs. Science 294:853-858.
4. Lau NC, Lim LP, Weinstein EG, Bartel DP (2001) An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294:858-862.
5. Lee RC, Ambros V (2001) An extensive class of small RNAs in Caenorhabditis elegans. Science 294:862-864.
6. Ratcliff FG, MacFarlane SA, Baulcombe DC (1999) Gene silencing without DNA. rnamediated cross-protection between viruses. Plant Cell 11:1207-1216.
7. Ketting RF, Haverkamp TH, van Luenen HG, Plasterk RH (1999) Mut-7 of C. elegans, required for transposon silencing and RNA interference, is a homolog of Werner syndrome helicase and RNaseD. Cell 99:133-141.
8. Harper SQ, et al. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102:5820-5825.
9. Rodriguez-Lebron E, et al. (2005) Intrastriatal rAAV-mediated delivery of antihuntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther 12:618-633.
10. Menalled LB, et al. (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 465:11-26.
11. Khvorova A, Reynolds A, Jayasena SD (2003) Functional siRNAs and miRNAs exhibit strand bias. Cell 115:209-216.
12. Reynolds A, et al. (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22:326-330.
13. Mittal V (2004) Improving the efficiency of RNA interference in mammals. Nat Rev Genet 5:355-365.
14. Zeng Y, Wagner EJ, Cullen BR (2002) Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 9:1327-1333.
15. Grimm D, et al. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-541.
16. Xia H, Mao Q, Paulson HL, Davidson BL (2002) siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 20:1006-1010.
17. Miller VM, et al. (2003) Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 100:7195-7200.
18. Gonzalez-Alegre P, Bode N, Davidson B, Paulson HL (2005) Silencing primary dystonia: Lentiviral-mediated RNA interference therapy for DYT1 dystonia. J Neurosci 25:10502-10509.
19. White JK, et al. (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 17:404-410.
20. Sandalon Z, et al. (2004) Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol 78:12355-12365.
21. Gao GP, et al. (1998) High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther 9:2353-2362.